Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
PR Newswire
RIDGEFIELD, Conn. and INGELHEIM, Germany, June 22, 2026
Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment optionsDAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig, Boehringer's immunoglobin G (IgG)-like bispecific T-cell engager, as a DLL3 biomarker-informed approach designed to help identify patients and inform treatment decisions for small cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC)1,2Beamion LUNG-3 will explore HERNEXEOS® (zongertinib tablets) in earlier stages of disease in resectable HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC), where new targeted treatment options are still needed3RIDGEFIELD, Conn. and INGELHEIM, Germany, June 22, 2026 /PRNewswire/ -- Boehringer Ingelheim is advancing biomarker-informed approaches and extending precision care across multiple cancers and stages of disease, reinforcing its ambition to bring unprecedented impact and improve long-term outcomes where unmet need remains high.4,5,6 The company has initiated two Phase III clinical trials within the DAREON® program: DAREON®-Lung-1 in small cell lung cancer (SCLC) and DAREON®-NEC-1 in extrapulmonary neuroendocrine carcinoma (epNEC). In parallel, the Phase III Beamion LUNG-3 trial has been initiated in HER2 (ERBB2)-mutant non-small cell lung cancer (NSCLC).4,5,6
